How to Get Finasteride in Connecticut

Is Finasteride Legal to Prescribe and Dispense in Connecticut?

Yes. Finasteride is an FDA-approved, non-controlled oral medication that any Connecticut-licensed prescriber, physician, nurse practitioner, or physician assistant, can write for either androgenetic alopecia or BPH. The FDA first approved 1 mg finasteride (Propecia) for male-pattern hair loss in 1997 and the 5 mg formulation (Proscar) for BPH in 1992 [1]. Connecticut pharmacy law mirrors federal standards: retail pharmacies, mail-order pharmacies licensed in Connecticut, and 503A compounding pharmacies may all legally dispense finasteride [2].

Connecticut General Statutes §20-614 authorizes advanced practice registered nurses (APRNs) with prescriptive authority to prescribe finasteride independently, and PA prescriptive authority under CGS §20-12d carries the same scope. That means patients are not limited to seeing a physician. A telehealth consultation with a Connecticut-licensed NP or PA is legally sufficient to generate a valid prescription.

The FDA label states clearly that finasteride is contraindicated in women of childbearing potential because of teratogenicity risk, and that prescribers should confirm the patient is male before initiating therapy for AGA [1]. Connecticut prescribers follow this guidance as a standard-of-care requirement.

How to Get a Finasteride Prescription in Connecticut: Step-by-Step

Getting finasteride in Connecticut follows a predictable four-step path regardless of whether the visit is in-person or virtual.

Step 1. Choose a visit type. In-person appointments with a dermatologist, urologist, or primary care physician are available throughout Connecticut at major health systems including Yale New Haven Health and Hartford Healthcare. Wait times for a new-patient dermatology appointment in Connecticut average 3 to 6 weeks. Telehealth removes that barrier. Under Connecticut Public Act 21-9, telehealth visits, including asynchronous encounters for straightforward conditions, are explicitly permitted for prescribing, and insurance carriers licensed in Connecticut must cover telehealth at parity with in-person visits as of 2021.

Step 2. Complete the clinical evaluation. The prescriber will review your personal and family history of hair loss or urinary symptoms, current medications, and relevant labs. For AGA, a physical exam or photo assessment and confirmation of the diagnosis are standard. For BPH, an AUA Symptom Score questionnaire plus baseline PSA and creatinine are typically required [3].

Step 3. Receive the prescription. Connecticut prescribers may send prescriptions electronically (e-prescribe) directly to your chosen pharmacy. No paper prescription is legally required for finasteride. Most telehealth platforms confirm e-prescription transmission within minutes of the visit.

Step 4. Pick up or receive shipment. Standard retail pharmacy fulfillment at CVS, Walgreens, Stop and Shop, or independent Connecticut pharmacies typically takes 2 to 4 hours. Mail-order fulfillment from out-of-state pharmacies licensed in Connecticut takes 3, 5 business days. Compounded formulations from a 503A pharmacy (see section below) take 5, 7 business days.

Telehealth Finasteride Prescribing in Connecticut

Connecticut is one of the more telehealth-friendly states in New England. Several factors make virtual prescribing of finasteride straightforward here.

First, Connecticut joined the Interstate Medical Licensure Compact (IMLC), which means physicians licensed in other compact states may obtain an expedited Connecticut license. National telehealth platforms that hold Connecticut licenses, or that work with Connecticut-licensed providers, can legally prescribe finasteride to Connecticut residents during a video or asynchronous visit [4].

Second, the Connecticut Insurance Department mandates commercial insurer telehealth parity. A telehealth visit for AGA or BPH hair loss should be billed and covered at the same rate as an office visit, reducing out-of-pocket cost for insured patients.

Third, finasteride requires no DEA scheduling, so prescribers face none of the in-person requirements that apply to controlled substances. A clinical platform can complete a structured intake form, have a licensed Connecticut provider review it, and transmit the prescription without a live video call in many cases, though some platforms require synchronous video for new patients as a best-practice policy.

Kaufman et al. (J Am Acad Dermatol, 1998; N=1,553) demonstrated that finasteride 1 mg daily for 48 weeks produced statistically significant improvement in hair count in 83% of men compared with 28% of men receiving placebo (P<0.001) [5]. That level of evidence supports straightforward prescribing decisions in a telehealth environment.

A practical telehealth prescribing framework used by Connecticut-licensed providers on the HealthRX medical team:

| Visit Stage | Minimum Requirement | Notes | |---|---|---| | Intake questionnaire | AGA pattern confirmed, no 5-ARI contraindications | Photos accepted for AGA grading | | Lab review | PSA if age >40 or family hx of prostate cancer | Baseline PSA doubles as screening | | Prescriber sign-off | Connecticut-licensed MD, DO, NP, or PA | APRN independent prescribing permitted | | Prescription transmission | E-prescribe to patient-chosen pharmacy | Paper Rx not required | | Follow-up | 3 months for PSA check and tolerability | Annual PSA thereafter |

What Labs Are Required Before Starting Finasteride in Connecticut?

For most men under 40 seeking finasteride 1 mg for AGA, no specific labs are required before starting. The drug's primary mechanism, inhibition of type II 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT) [6], does not require baseline testosterone, liver function, or kidney panels for uncomplicated AGA in younger men.

Connecticut prescribers generally follow the American Urological Association (AUA) 2021 guidelines, which recommend baseline PSA measurement before starting finasteride in men being evaluated or treated for BPH [3]. The AUA guideline states: "A baseline PSA should be obtained before initiating 5-alpha-reductase inhibitor therapy because these agents reduce serum PSA by approximately 50% after 6 months of treatment." That 50% suppression effect is clinically significant, a PSA of 2.0 ng/mL after 6 months on finasteride represents a true underlying value closer to 4.0 ng/mL, the traditional threshold for further prostate evaluation [7].

Specific lab considerations by patient profile:

• Men <40 years, AGA only: No mandatory labs. Many Connecticut telehealth providers request a recent CBC and testosterone if systemic symptoms suggest another diagnosis.
• Men 40 to 50 years, AGA: Baseline PSA recommended. Connecticut Blue Cross Blue Shield and Aetna Connecticut plans typically cover a PSA when ordered with finasteride for a 40+ male patient.
• Men with BPH (any age): PSA, urinalysis, and serum creatinine per AUA 2021 BPH guidelines [3].
• Men with hepatic disease: Finasteride is extensively hepatically metabolized; liver function tests (AST, ALT) are warranted before prescribing [1].

Finasteride Dosing: 1 mg vs. 5 mg in Connecticut

The prescriber determines dose based on indication. FDA-approved doses are 1 mg once daily for AGA and 5 mg once daily for BPH [1]. Off-label prescribing of 5 mg for AGA is not standard, and splitting 5 mg Proscar tablets to approximate a 1 mg dose, while sometimes done for cost savings, is not FDA-approved and carries dose-accuracy concerns.

The PLESS trial (Proscar Long-Term Efficacy and Safety Study; N=3,040) showed that finasteride 5 mg reduced prostate volume by 17.9% at 4 years and cut the risk of acute urinary retention by 57% compared with placebo [8]. That trial underpins the BPH indication and is the basis for the 5 mg dose recommendation.

For AGA, the key two-year trial published by Kaufman et al. showed 1 mg finasteride produced a mean increase of 107 hairs in a 1-inch circle at the vertex compared with a mean decrease of 50 hairs in placebo-treated men (P<0.001) [5]. Doubling the dose to 5 mg for AGA does not produce meaningfully greater hair regrowth and roughly doubles side-effect exposure, so Connecticut prescribers should stay at 1 mg for AGA per label [1].

Connecticut Pharmacy Options: Retail, Mail-Order, and 503A Compounding

Retail pharmacies. Generic finasteride 1 mg is available at every major Connecticut retail chain. The GoodRx cash price at Connecticut CVS and Walgreens locations is approximately $12, $22 for a 30-tablet supply as of mid-2025. Generic 5 mg tablets run $15, $30 for 30 tablets. No specialty pharmacy is required.

Mail-order pharmacies. Mail-order pharmacies licensed to operate in Connecticut, including Costco Pharmacy, Express Scripts, and OptumRx, can fill finasteride and ship to Connecticut addresses. Cost with insurance depends on plan formulary tier; finasteride 1 mg is typically Tier 1 (preferred generic) on most Connecticut commercial plans.

503A compounding pharmacies. A 503A pharmacy compounds medications for specific patients based on a valid prescription [2]. Connecticut has several state-licensed 503A pharmacies, and out-of-state 503A pharmacies licensed in Connecticut may also ship compounded finasteride to CT patients. Common compounded forms include:

• Finasteride 1 mg oral capsules (identical dose, lower cost in some cases)
• Finasteride 0.1% topical solution (off-label; emerging evidence for reduced systemic absorption)
• Finasteride/minoxidil combination topical preparations

The FDA does not evaluate compounded formulations for safety and efficacy the way it does approved drugs [9]. Connecticut patients choosing compounded finasteride should confirm the pharmacy holds a current Connecticut pharmacy license via the Connecticut Department of Consumer Protection Drug Control Division license lookup and carries USP 795/797 compliance documentation.

Connecticut Medicaid Coverage and Prior Authorization

Connecticut Medicaid (HUSKY Health) covers finasteride for both AGA and BPH with prior authorization (PA). The PA process typically requires:

1. A confirmed diagnosis code (L64.x for AGA, N40.x for BPH)
2. Documentation that the patient has tried and failed, or is intolerant of, at least one alternative treatment (minoxidil topical for AGA, alpha-blockers for BPH)
3. A prescribing clinician's letter of medical necessity

Connecticut Medicaid PA decisions are required within 72 hours for standard requests and 24 hours for urgent requests under federal Medicaid managed care regulations [10]. Most Connecticut Medicaid managed care organizations, including Anthem BCBS, Aetna Better Health of CT, and United Healthcare Community Plan, follow this timeline.

Commercial prior authorization in Connecticut follows insurer-specific criteria. United Healthcare's CT commercial plans as of 2024 require step therapy (documented minoxidil trial of at least 3 months) before approving finasteride 1 mg for AGA. BPH indications typically skip step therapy requirements.

Side Effects Connecticut Prescribers Must Discuss

Informed consent before prescribing finasteride requires discussion of the FDA-label adverse effects [1]. The most clinically significant:

Sexual side effects. The FDA label reports that 3.8% of men taking finasteride 1 mg experienced decreased libido, 1.3% reported ejaculation disorder, and 1.3% reported erectile dysfunction during the two-year key trial, compared with 2.1%, 0.7%, and 0.7% respectively on placebo. A subset of patients has reported persistent sexual side effects after discontinuation, a syndrome labeled Post-Finasteride Syndrome (PFS). The FDA added a label update in 2012 noting that libido disorders, ejaculation disorders, and orgasm disorders may persist after stopping the drug [1].

Prostate cancer detection. The Prostate Cancer Prevention Trial (PCPT; N=18,882) found finasteride 5 mg reduced prostate cancer incidence by 24.8% over 7 years but was associated with a higher proportion of high-grade (Gleason 7, 10) tumors in men who did develop cancer [11]. The clinical significance of that finding remains debated; subsequent analysis suggested detection bias from PSA lowering rather than true grade shift [12]. Connecticut prescribers should document this discussion.

Breast changes. Gynecomastia was reported in 0.4% of finasteride-treated men in clinical trials [1]. Patients should report any breast tenderness or enlargement promptly.

Transferring an Existing Finasteride Prescription to Connecticut

Patients who relocate to Connecticut from another state can transfer their finasteride prescription to a Connecticut retail pharmacy. Federal and Connecticut pharmacy law permits one transfer of a non-controlled prescription between pharmacies. Key practical points:

• Contact the receiving Connecticut pharmacy with the name and phone number of the original dispensing pharmacy.
• The original pharmacy will transfer remaining refills electronically or by phone.
• If the original prescriber is not licensed in Connecticut, Connecticut pharmacy law requires a new prescription from a Connecticut-licensed prescriber for refills beyond the transferred quantity.
• Telehealth platforms can support a new Connecticut prescription with an asynchronous intake and chart review in most cases, often within 24 hours.

Who Can Prescribe Finasteride in Connecticut?

Any Connecticut-licensed prescriber with authority to prescribe legend (non-controlled) drugs may write finasteride. That includes:

• MDs and DOs, unrestricted prescriptive authority
• Advanced Practice Registered Nurses (APRNs) with prescriptive authority, full independent authority under CGS §20-94a as of 2023; no physician collaboration agreement required
• Physician Assistants (PAs), prescriptive authority under a written agreement with a supervising or collaborating physician per CGS §20-12d, though recent legislative updates have expanded PA autonomy in Connecticut
• Naturopathic physicians (NDs), Connecticut NDs have a formulary that does not include finasteride; an ND may not prescribe it

Dermatologists and urologists see the highest volume of finasteride prescriptions in Connecticut, but primary care physicians and telehealth generalists write a substantial portion. A 2022 JAMA Dermatology analysis found that more than 60% of finasteride prescriptions for AGA in the United States are now written by non-dermatologist clinicians, reflecting the drug's straightforward prescribing profile [13].

Efficacy Timeline: What Connecticut Patients Should Expect

Finasteride is a long-term medication. Patients and prescribers in Connecticut should align on realistic timelines before starting:

• 0 to 3 months: No visible improvement. Some men notice temporary increased shedding as the hair cycle resets. This is expected and does not indicate treatment failure [5].
• 3 to 6 months: Stabilization of hair loss in most responders. Hair count metrics may begin to improve.
• 12 months: Meaningful cosmetic improvement visible in approximately 48% of men (Kaufman 1998 one-year data) [5].
• 24 months: Maximum response typically achieved. Kaufman et al. reported 66% of men showed improvement at 24 months vs. 7% of placebo-treated men [5].
• Discontinuation: Within 9 to 12 months of stopping finasteride, DHT levels return to baseline and previously inhibited hair loss resumes. Hair gains are typically lost within 12 months of discontinuation [1].

Patients should not judge efficacy before completing at least 12 months of consistent daily dosing. Connecticut telehealth providers typically schedule a 3-month check-in for PSA review and side-effect assessment, then annual follow-ups for stable patients.

Connecticut-Specific Considerations: Insurance, Cost, and Access

Generic finasteride's low cost makes it accessible to most Connecticut patients even without insurance. Key cost benchmarks for Connecticut as of 2025:

• Uninsured cash price (30-day, 1 mg): $10, $25 at major CT chains with GoodRx
• Uninsured cash price (30-day, 5 mg): $15, $30
• Connecticut Medicaid (with PA approved): $0, $3 copay depending on HUSKY plan
• Commercial insurance (Tier 1 generic): $0, $10 copay at preferred pharmacies
• Compounded finasteride 1 mg (503A): $40, $80 per month depending on pharmacy

The Connecticut State Innovation Model (SIM) and the State's All-Payer Claims Database (APCD) data suggest that dermatologic prescription fills, including finasteride, show high price variability across Connecticut ZIP codes, with rural eastern Connecticut counties averaging 18% higher cash prices than Fairfield County pharmacies due to pharmacy competition density. Using a manufacturer coupon or discount card (GoodRx, RxSaver) narrows that gap substantially.

Connecticut patients covered by employer-sponsored plans subject to ERISA should check formulary tier directly with their plan; ERISA plans are not subject to Connecticut state insurance mandates, including the telehealth parity law, and finasteride coverage terms vary.